Also known as GDC-6036 and RG6330.
Phase III Krascendo 1: divarasib reduced risk of progression/death by 42% and risk of death by 44%; median OS ~17.7 vs 12.0 months; ORR 58% vs 32%; manageable safety.
Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.
